Business Context and Reporting Period
Company: Stevanato Group S.p.A.
Filing Type: Form 6-K (Interim Condensed Consolidated Financial Statements)
Reporting Period: Three and nine months ended September 30, 2021
Business Overview: A global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical and biotechnology industries. Operations are organized into two segments: Biopharmaceutical and Diagnostic Solutions (containment, delivery systems, medical devices) and Engineering (machinery and equipment). The company completed its Initial Public Offering (IPO) on the NYSE in July 2021.
Key Financial Metrics
| Metric (EUR millions) | 9 Months Ended Sep 30, 2021 | 9 Months Ended Sep 30, 2020 | 3 Months Ended Sep 30, 2021 | 3 Months Ended Sep 30, 2020 |
|---|---|---|---|---|
| Revenues | 611.3 | 455.3 | 214.5 | 157.1 |
| Gross Profit | 192.4 | 135.6 | 63.3 | 47.2 |
| Gross Margin | 31.5% | 29.8% | 29.5% | 30.1% |
| Operating Profit | 118.8 | 65.2 | 28.2 | 22.7 |
| Operating Margin | 19.4% | 14.3% | 13.2% | 14.4% |
| Net Profit (Attributable to Parent) | 89.6 | 44.7 | 18.7 | 16.6 |
| EBITDA | 160.1 | 104.1 | 43.2 | 35.9 |
| Free Cash Flow | 5.8 | 34.2 | (9.9) | 30.9 |
| Cash and Cash Equivalents (Sep 30, 2021) | 428.0 | — | — | — |
| Total Debt (Financial Liabilities) | 302.9 | — | — | — |
Note: Debt figures represent total financial liabilities as of September 30, 2021. Prior period debt figures are not explicitly summarized in the highlights table but are detailed in the notes (Total financial liabilities Dec 31, 2020: EUR 375.4 million).
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased by 34.3% (9 months) and 36.5% (3 months) year-over-year. Growth was driven by both segments, with the Engineering segment seeing a 70.8% increase (9 months) due to high order intake for visual inspection and glass forming machines. The Biopharmaceutical segment grew 28.7% (9 months), aided by COVID-19 vaccine demand (estimated at 14.8% of total revenue for the 9-month period).
- Profitability: Operating profit surged 82.2% for the nine months ended September 30, 2021. Net profit attributable to equity holders doubled (100.5% increase) to EUR 89.6 million.
- Cost Structure: Cost of sales increased 31.1% (9 months), less than proportionally to revenue, due to efficiency maximization. However, General and Administrative expenses included significant non-recurring items (see below).
- Liquidity: Cash and cash equivalents increased significantly from EUR 115.6 million (Dec 31, 2020) to EUR 428.0 million (Sep 30, 2021), primarily due to IPO proceeds of approximately EUR 380.2 million.
Guidance, Outlook, and Unusual Items
Management Commentary and Outlook
- Backlog: As of September 30, 2021, backlog stood at EUR 834.3 million, up from EUR 606.7 million at year-end 2020. New order intake in Q3 2021 was EUR 309.9 million.
- Expansion: The company announced the start of construction on a new facility in Fishers, Indiana (USA), expected to be operational in 2023 with an investment of approximately USD 145 million. Expansion is also underway in Piombino Dese, Italy.
- COVID-19 Impact: Management anticipates demand for syringes and vials will remain elevated due to global vaccination roll-outs and booster shots, though uncertainty remains regarding long-term demand magnitude.
Unusual Items and Non-GAAP Adjustments
Reported results for the nine months ended September 30, 2021, were impacted by several non-recurring items:
- Patent Box Regime: A retroactive tax saving of EUR 7.1 million related to an agreement with the Italian Tax Agency (EUR 5.5 million recognized in Q1, EUR 1.6 million in Q3).
- Incentive Plans: A non-recurring accrual reversal of EUR 9.9 million related to the early termination of legacy incentive plans (2012-2021 and 2018-2022).
- Out-of-Cycle Bonus: A discretionary bonus to personnel of EUR 6.7 million.
- IPO Costs: EUR 0.7 million in listing expenses and EUR 4.3 million foreign exchange loss on derivatives hedging IPO proceeds.
- Adjusted Metrics: Adjusted Operating Profit for the nine months was EUR 118.1 million (Adjusted Margin 19.3%). Adjusted Net Profit was EUR 87.5 million.
Risks
- Market Risks: Exposure to foreign currency exchange rates (USD, BRL, CNY) and interest rates. The company uses derivatives to hedge these risks.
- Operational Risks: Dependence on key management, supply chain disruptions, and the complexity of product offerings.
- Legal: Ongoing litigation and regulatory proceedings, though management does not expect a material effect on financial condition.
Investor Verification Checklist
- Revenue Quality: Verify the sustainability of the 14.8% revenue contribution from COVID-19 related products post-vaccination peak.
- Non-Recurring Items: Assess the impact of the EUR 9.9 million incentive plan reversal and EUR 7.1 million tax benefit on normalized earnings.
- Capital Expenditure: Monitor the execution and cost of the new USD 145 million Indiana facility and other capacity expansions.
- Working Capital: Review the increase in trade receivables (EUR 154.7 million) and contract assets (EUR 64.5 million) relative to revenue growth.
- Debt Profile: Analyze the reduction in total financial liabilities from EUR 375.4 million (Dec 2020) to EUR 302.9 million (Sep 2021) and future debt service obligations.